source
- Tessera Therapeutics reports infusion gene edit corrects 85% of blood cells in sickle cell studyTessera Therapeutics announced new data from its in-vivo gene editing program targeting sickle cell disease. The experimental therapy is given as a simple infusion, avoiding the complex cell engin…
- Biomarker testing guides endometrial cancer treatment and highlights gaps in second-line options after immunotherapyThe discussion highlighted that performing biomarker testing at diagnosis is now standard for endometrial cancer, helping decide between targeted therapies and immunotherapy. The experts described…